title: What can we expect from biomarkers for acute kidney injury?
abstract: Biomarkers for acute kidney injury have numerous potential roles to play both at the bedside and in the design and conduct of clinical trials. Given the heterogeneous nature of this disease and the difficulty, so far, in developing effective therapies, a strategy that deploys all of our available tools in the treatment and in study of treatments would seem prudent. In this review, we discuss how biomarkers will change the way we do we take care of patients with and do clinical trials in acute kidney injury and why, in fact, biomarkers are necessary.
authors.affiliation: Center for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh School of Medicine, 604, Scaife Hall, 3550 Terrace Street, Pittsburgh, PA 15261, USA.
authors.forename: John A
authors.initials: JA
authors.lastname: Kellum
authors.forename: Prasad
authors.initials: P
authors.lastname: Devarajan
mesh_terms: D058186:Acute Kidney Injury / Q000097:blood / Q000175:diagnosis* / Q000652:urine; D015415:Biomarkers / Q000032:analysis* / Q000097:blood / Q000652:urine; D002986:Clinical Trials as Topic; D006801:Humans
chemical_list: D015415:Biomarkers
keywords: acute kidney injury; acute renal failure; biomarkers; clinical trial design; diagnostics; risk assessment